|Articles|March 1, 1998

March 1998
Volume 4
Issue 3

A Cost-Effectiveness Clinical Decision Analysis Model for Schizophrenia

Author(s)Cynthia S. Palmer, MSc, Dennis A. Revicki, PhD, Laura A. Genduso, PharmD

Download PDF: A Cost-Effectiveness Clinical Decision Analysis Model for Schizophrenia

Articles in this issue

over 28 years ago

Article

Identifying Diabetes Mellitus or Heart Disease Among Health Maintenance Organization Members: Sensitivity, Specificity, Predictive Value, and Cost of Survey and Database Methods

over 28 years ago

Article

Economic Outcomes Associated with the Use of Risperidone in a Naturalistic Group Practice Setting

over 28 years ago

Article

Treatment of Schizophrenia: Let's Talk Dollars and Sense

over 28 years ago

Article

Maintaining Skeletal Health Among Postmenopausal Women

over 28 years ago

Article

Prevalence and Cost of Hospitalization for Gastrointestinal Complications Related to Peptic Ulcers with Bleeding or Perforation: Comparison of Two National Databases

over 28 years ago

Article

Virtual Managed Care Organizations: The Implications of Technology-Based Patient Management

over 28 years ago

Article

Work-up for Diverticulitis

over 28 years ago

Article

Screening and Surveillance for Colorectal Cancer

over 28 years ago

Article

Parenteral and Enteral Nutrition in the Home and Chronic Care Settings

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

Cleveland | Image credit: Francis Angelone - stock.adobe.com

September 17th, 2026

Prescribing Gaps Persist in CKM Care Even as Therapies Multiply

New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.

Woman stepping on scale | Image credit: Hunterframe - stock.adobe.com

September 16th, 2026

Across the US, Obesity Care Still Lacks an Owner

Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.

Chest pain | Image credit: lovelyday12 - stock.adobe.com

September 16th, 2026

HFpEF, HFmrEF Care Still Lags Behind the Evidence, Experts Say

Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.

A Cost-Effectiveness Clinical Decision Analysis Model for Schizophrenia

Articles in this issue

Related to this article

Trending on AJMC

FDA Approves First Treatment for Sanfilippo Syndrome Type A

Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared

No Blood Biomarker Is Ready to Pick Psoriasis Therapy

Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD

Specialty Pharmacy Leaders to Convene for NASP inSPire2026